Innovative retatrutide, a dual -action drug targeting simultaneously GLP-1 and GIP receptors, is generating considerable excitement within the weight loss community. Early clinical trials have revealed substantial decreases in physical weight and gains in metabolic markers for people with excess weight . Researchers believe this novel approach cou